PBK and prostate adenocarcinoma: Consistently, data from the TIMER 2.0 database (https://compbio.cn/timer2/) show that TOPK/PBK is upregulated in multiple cancers, including BLCA, BRCA, CESC, cholangio carcinoma (CHOL), COAD, ESCA, GBM, head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), LIHC, LUAD, LUSC, PAAD, pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), SKCM with metastasis, STAD, thyroid carcinoma (THCA), while showing reduced expression in LAML and TGCT (Supplement Figure 2B) 20-22.